Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;34(1):e14305.
doi: 10.1111/nmo.14305. Epub 2021 Dec 3.

Pain in irritable bowel syndrome: Does anything really help?

Affiliations
Review

Pain in irritable bowel syndrome: Does anything really help?

Joelle BouSaba et al. Neurogastroenterol Motil. 2022 Jan.

Abstract

Pain relief remains a significant challenge in the management of irritable bowel syndrome (IBS): "Does anything really help relieve the pain in patients with IBS?". Interventions aimed at pain relief in patients with IBS include diet, probiotics or antibiotics, antidepressants, antispasmodics, and drugs targeting specific gastrointestinal receptors such as opioid or histamine receptors. In the systematic review and meta-analysis published in this journal, Lambarth et al. examined the literature on the role of oral and parenteral anti-neuropathic agents in the management of pain in patients with IBS. This review article appraises their assessment of the efficacy of the anti-neuropathic agents amitriptyline, pregabalin, gabapentin, and duloxetine in the relief of abdominal pain or discomfort, and impact on overall IBS severity and quality of life. This commentary provides an update of current evidence on the efficacy of the dietary and pharmacological treatments that are available or in development, as well psychological and cognitive behavioral therapy for pain in IBS. Advances in recent years augur well for efficacious treatments that may expand the therapeutic arsenal for pain in IBS.

Keywords: antispasmodics; hypnotherapy; neuromodulators; peppermint oil; psychotherapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors have no conflicts of interest.

Comment on

Similar articles

Cited by

References

    1. Lambarth A, Zarate-Lopez N, Fayaz A. Oral and parenteral anti-neuropathic agents for the management of pain and discomfort in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil. 2021:e14289. - PubMed
    1. Black CJ, Yuan Y, Selinger CP, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(2):117–131. - PubMed
    1. Camilleri M. Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. Jama. 2021;325(9):865–877. - PubMed
    1. Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017;66(5):966–974. - PubMed
    1. Wald A Constipation: Advances in Diagnosis and Treatment. Jama. 2016;315(2):185–191. - PubMed

Publication types

MeSH terms